Curcumin-artemisinin coamorphous solid: Xenograft model preclinical study

TitleCurcumin-artemisinin coamorphous solid: Xenograft model preclinical study
Publication TypeJournal Article
Year of Publication2018
AuthorsMannava, MKChaitan, Suresh, K, Bommaka, MKumar, Konga, DBhavani, Nangia, A
JournalPharmaceutics
Volume10
Issue1
PaginationArticle Number: 7
Date PublishedMAR
AbstractCurcumin is a natural compound present in Indian spice turmeric. It has diverse pharmacological action but low oral solubility and bioavailability continue to limit its use as a drug. With the aim of improving the bioavailability of Curcumin (CUR), we evaluated Curcumin-Pyrogallol (CUR-PYR) cocrystal and Curcumin-Artemisinin (CUR-ART) coamorphous solid. Both of these solid forms exhibited superior dissolution and pharmacokinetic behavior compared to pure CUR, which is practically insoluble in water. CUR-ART coamorphous solid showed two fold higher bioavailability than CUR-PYR cocrystal (at 200 mg/kg oral dose). Moreover, in simulated gastric and intestinal fluids (SGF and SIF), CUR-ART is stable up to 3 and 12 h, respectively. In addition, CUR-PYR and CUR-ART showed no adverse effects in toxicology studies (10 times higher dose at 2000 mg/kg). CUR-ART showed higher therapeutic effect and inhibited approximately 62% of tumor growth at 100 mg/kg oral dosage of CUR in xenograft models, which is equal to the positive control drug, doxorubicin (2 mg/kg) by i.v. administration.
DOI10.3390/pharmaceutics10010007
Type of Journal (Indian or Foreign)Foreign
Impact Factor (IF)3.649
Divison category: 
Physical and Materials Chemistry

Add new comment